First patients to test new pill targeting advanced cancers
NCT ID NCT06784193
Summary
This is the first study in people testing a new oral drug called OP-3136 for advanced or metastatic cancers, including certain types of breast, prostate, and lung cancer. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help control the cancer. The study will test the drug by itself and in combination with other approved cancer medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research South Australia
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
START - Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START - Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
START - San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
University Medical Center - New Orleans
RECRUITINGNew Orleans, Louisiana, 70112, United States
Conditions
Explore the condition pages connected to this study.